Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIND1 System in Schizophrenia or Bipolar I Disorder
NCT01981811Phase 2Withdrawn
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Mar 2014
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aripiprazole in schizophrenia and bipolar I disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Medication adherence. Planned start Mar 2014; status: withdrawn.
02
Drugs
aripiprazole
03
Conditions
schizophreniabipolar I disorder
Beyond the preview
Go deeper on NCT01981811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01981811.